The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
 
Robin Kate Kelley
Consulting or Advisory Role - Bayer (Inst)
Research Funding - Agios; Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Tae-You Kim
No Relationships to Disclose
 
Mitesh J. Borad
No Relationships to Disclose
 
Wei-Peng Yong
Honoraria - MSD; Taiho Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - MSD; Roche; Taiho Pharmaceutical
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Bayer; Novartis; Roche/Genentech
 
Marlon Rebelatto
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
Patents, Royalties, Other Intellectual Property - MedImmune (Inst)
 
Mallory Makowsky
No Relationships to Disclose
 
Feng Xiao
Employment - MedImmune; MedImmune (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); GlaxoSmithKline; GlaxoSmithKline (I)
 
Shannon R. Morris
Employment - AstraZeneca; MedImmune
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - MedImmune
Travel, Accommodations, Expenses - AstraZeneca; MedImmune
 
Bruno Sangro
Consulting or Advisory Role - Adaptimmune; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; BTG; Merck; Sirtex Medical
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Sirtex Medical